AbCellera Biologics Inc. (ABCL) Operating cash flow 2019–2025
AbCellera Biologics Inc. (ABCL) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$131.3MFY2025 · since FY2019: $2.7M → -$131.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$131.3M | -20.9% |
| FY2024 | -$108.6M | -147.4% |
| FY2023 | -$43.9M | -115.8% |
| FY2022 | $277.4M | +13.4% |
| FY2021 | $244.6M | +977.9% |
| FY2020 | $22.7M | +742.2% |
| FY2019 | $2.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Net marginABCL Gross profitABCL Gross marginABCL Operating incomeABCL Operating marginABCL Free cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Total liabilitiesABCL Shareholders’ equityABCL overview →